Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $15 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $15 price target.
Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $15 price target.